Reviva Pharmaceuticals Holdings Inc. (RVPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Reviva Pharmaceuticals Holdings Inc. (RVPH) has a cash flow conversion efficiency ratio of -2.844x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-24.59 Trillion) by net assets ($8.65 Trillion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See RVPH cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Reviva Pharmaceuticals Holdings Inc. - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Reviva Pharmaceuticals Holdings Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Reviva Pharmaceuticals Holdings Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Reviva Pharmaceuticals Holdings Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Anmol India Limited
NSE:ANMOL
|
0.002x |
|
TruCap Finance Limited
NSE:TRU
|
1.175x |
|
Superior Resources Ltd
AU:SPQ
|
-0.025x |
|
DEFSEC Technologies Inc.
NASDAQ:DFSC
|
-0.430x |
|
CARTIER SILVER CORP
F:2CI0
|
N/A |
|
Hube Yangfan Holding Co Ltd
SHG:600421
|
-0.156x |
|
Mitra Energi Persada Tbk PT
JK:KOPI
|
0.077x |
|
COMTEC SOLAR SYS HD -004
F:8C11
|
N/A |
Annual Cash Flow Conversion Efficiency for Reviva Pharmaceuticals Holdings Inc. (2018–2025)
The table below shows the annual cash flow conversion efficiency of Reviva Pharmaceuticals Holdings Inc. from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Reviva Pharmaceuticals Holdings Inc..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $8.65 Trillion | $-24.59 Trillion | -2.844x | +93.11% |
| 2024-12-31 | $812.57K | $-33.54 Million | -41.281x | -733.47% |
| 2023-12-31 | $5.72 Million | $-28.32 Million | -4.953x | -119.28% |
| 2022-12-31 | $8.39 Million | $-18.96 Million | -2.259x | -507.36% |
| 2021-12-31 | $28.69 Million | $-10.67 Million | -0.372x | +50.01% |
| 2020-12-31 | $5.47 Million | $-4.07 Million | -0.744x | -2419.97% |
| 2019-12-31 | $-6.81 Million | $-218.44K | 0.032x | +277.08% |
| 2018-12-31 | $59.16 Million | $-1.07 Million | -0.018x | -- |
About Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, s… Read more